Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has issued an update.
Shanghai Fosun Pharmaceutical announced that its subsidiary’s FCN-159 tablets have been granted breakthrough therapy designation by the National Medical Products Administration for treating children with Langerhans cell histiocytosis. This designation highlights the company’s commitment to developing innovative treatments and may enhance its position in the pharmaceutical industry, potentially benefiting stakeholders by accelerating the drug’s development and approval process.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock limited company incorporated in China, operating in the pharmaceutical industry. The company focuses on the development and manufacturing of innovative drugs, with a market focus on advanced solid tumors, neurofibromatosis type 1, and other related conditions.
YTD Price Performance: -2.41%
Average Trading Volume: 5,593,387
Technical Sentiment Signal: Sell
Current Market Cap: HK$61.09B
Find detailed analytics on 2196 stock on TipRanks’ Stock Analysis page.